TTM2-TAME Trial

All Done!

A bit more to do?    Log in


The latest from the Spiral blog . . .

It's official! The Panoramic trial is all go!

2021-12-16



Recently we announced our involvement in another incredibly exciting trial, aimed at finding effective treatments for people in the community which will prevent people from being hospitalised with Covid-19.

This trial was awarded funding through the National Institute for Health Research (NIHR) to work with several UK universities and carry out a first-of-its-kind clinical trial, testing novel antiviral COVID-19 treatments for use early on in the illness by people in the community with COVID-19 who are at higher risk of complications.

Known as PANORAMIC, this trial is led by Oxford University’s Primary Care Clinical Trials Unit, while the delivery of the trial will be supported by the NIHR Clinical Research Network and devolved administrations.

In a new development, we’re thrilled to report that the UK government has announced that thousands of the UK’s most vulnerable people will be among the first in the world to access these life-saving, cutting-edge antiviral and antibody treatments from December.

“This opens up a new era for the treatment of COVID-19, one where we can begin to cover every phase of contracting this deadly disease – whether it be before you catch it, just after you catch it, if you develop symptoms or if you require hospital care.” - UK Health and Social Care Secretary Sajid Javid

The study will be trialling the use of Molnupiravir, an anti-viral drug shown in clinical trials to reduce the risk of hospitalisation or death for at-risk, non-hospitalised adults with mild to moderate COVID-19 by 30%.

Taking part in the study will require participants to complete a daily diary for 28 days through the PANORAMIC website or receive a phone call from the trial team on days 7, 14 and 28 to speak about their symptoms. The first set of results from the trial is anticipated in early 2022.

Spiral will be supporting with our savvy software platform and our ability to pivot with change. Unlike others, we can adapt our platform for Novel Trials or studies that use unusual design methodologies. We’re excited to keep you informed about this groundbreaking trial - one that we feel privileged to be a part of.

Keep up to date with the Panoramic trial via our Trial Hub page here. We will be refreshing it with new information as and when it is made available.

Dive Deeper:

Press Release - UK’S Most Vulnerable People to receive life-saving Covid-19 treatments in the community



 
 

Follow us on Twitter

     
 

Like us on Facebook




 

About the TTM2 Study

The TTM2 trial is a phase III, multi-centre, randomized, parallel-group, clinical trial in resuscitated cardiac arrest patients admitted to the intensive care unit to investigate whether targeted temperature management (TTM) to 33°C improves survival and neurological outcome at 6 months compared to a strategy of targeting normothermia and avoiding fever above 37.7°C. More information »

About the TAME Study

The TAME trial is a phase III, multi-centre, randomised, parallel-group, clinical trial in resuscitated cardiac arrest patients admitted to the intensive care unit to determine whether targeted therapeutic mild hypercapnia (TTMH) improves neurological outcome at 6 months compared to standard care (targeted normocapnia) (TN). More information »

About the software

Spinnaker is a tailored, web based, software and database solution for managing your multi-centre clinical study including the recording of patient data, recording and alerting of events, inventory management and reporting on data collected during the course of your study. Spinnaker is user friendly, adaptable and can be delivered quickly. You can read more on the Spinnaker website or contact Audrey on spinnaker@spiral.co.nz.

 

You can get to know us a little better through our blog and social media pages accessed via the logout screen of this trial.